Last reviewed · How we verify
S-1 therapy
S-1 therapy is a chemotherapy medication that works by inhibiting thymidylate synthase, thereby preventing DNA synthesis and cell division.
S-1 therapy is a chemotherapy medication that works by inhibiting thymidylate synthase, thereby preventing DNA synthesis and cell division. Used for Advanced gastric cancer, Pancreatic cancer.
At a glance
| Generic name | S-1 therapy |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Drug class | Antimetabolite |
| Target | Thymidylate synthase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
S-1 is a prodrug that is converted into its active components, 5-fluorouracil (5-FU), 5-deoxy-5-fluoruridine (5-DFUR), and alanosine. These components then inhibit thymidylate synthase, which is essential for DNA synthesis and cell division. This leads to the death of rapidly dividing cancer cells.
Approved indications
- Advanced gastric cancer
- Pancreatic cancer
Common side effects
- Diarrhea
- Nausea and vomiting
- Fatigue
- Anemia
- Neutropenia
Key clinical trials
- Patient Satisfaction During Lomber Transforaminal Epidural Steroid Injection: The Role of Sedation, Anxiety, and Pain
- Testing the Addition of an Anti-cancer Drug, Navtemadlin, to the Usual Treatments (Cytarabine and Idarubicin) in Patients With Acute Myeloid Leukemia (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- Testing Trametinib as a Potential Targeted Treatment in Cancers With NF1 Genetic Changes (MATCH-Subprotocol S1) (PHASE2)
- Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination With Decitabine and Venetoclax in Patients With Acute Myeloid Leukemia (PHASE1)
- Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) (PHASE2)
- Durvalumab With Chemotherapy as First Line Treatment in Patients With Advanced Biliary Tract Cancers (aBTCs) (PHASE3)
- A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |